Bumetanide Salt Formulations That Bypass Oral Diuretic Failure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for edema refractory to oral diuretics, such as those seen in congestive heart failure, often require hospitalization and can lead to kidney failure due to ineffective fluid removal, particularly when gastrointestinal absorption is compromised.
Innovation Solution
A pharmaceutical composition comprising an aqueous solution of potassium or arginine bumetanide salt, with specific pH and concentration ranges, and pharmaceutically acceptable excipients, is administered intranasally, sublingually, or subcutaneously to bypass gastrointestinal absorption and achieve effective diuresis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral diuretics are administered to patients with edema, then fluid removal is attempted, but gastrointestinal absorption is compromised rendering the treatment ineffective
Solution Approach 1:
The invention divides the administration route into separate segments - using intranasal, sublingual, or transdermal pathways independently of the compromised gastrointestinal system. This allows the diuretic agent to bypass the dysfunctional absorption pathway entirely while still achieving systemic delivery.
Solution Approach 2:
The patent introduces alternative absorption intermediaries (nasal mucosa, sublingual tissue, or transdermal layer) that can effectively transfer the diuretic agent into the bloodstream without relying on the compromised gastrointestinal system. These intermediary pathways restore reliable drug delivery.
2Reliability
If intravenous diuretics are administered to bypass gastrointestinal absorption, then fluid removal effectiveness is improved, but hospitalization is required and patient convenience deteriorates
Solution Approach 1:
The invention enables patients to self-administer diuretic therapy at home using simple intranasal, sublingual, or transdermal application. This eliminates the need for hospital-based intravenous administration while maintaining treatment effectiveness, allowing patients to manage their own care.
Solution Approach 2:
The patent replaces the complex mechanical intravenous administration system (requiring hospitals, equipment, and professionals) with simple self-administered formulations that can be applied at home, dramatically improving patient convenience while maintaining reliability.
3Productivity
If oral diuretic dosage is increased to overcome poor absorption, then attempted fluid removal is enhanced, but kidney strain increases leading to potential kidney failure
Solution Approach 1:
The invention changes the administration parameter from oral to alternative routes (intranasal, sublingual, transdermal), which fundamentally alters the absorption kinetics. This allows achieving effective plasma concentrations without the need for high dosages that would strain the kidneys, thereby maintaining productivity while reducing harmful effects.
Data Source
AI summary
The present invention features methods and compositions for the intranasal, sublingual, and subcutaneous administration of bumetanide for the treatment of subjects suffering from edema refractory to oral diuretics.